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Adenocarcinoma of the prostate is one of the most frequently
diagnosed malignancies in Western countries and, following lung
cancer, it has become one of the most common causes of death
from cancer within the male population (Parker et al, 1996). While
some patients die soon after diagnosis, other patients with ‘latent’
tumours will never suffer from any symptoms during their life-
time. This observation indicates the highly variable biological
potential of prostate cancer and demonstrates the need for prog-
nostic factors to determine the clinical prognosis of the individual
patient and to guide currently available treatment options to a
more aggressive (radical prostatectomy) or conservative (surveil-
lance) approach (George, 1988; Adolfsson et al, 1992; Johanssen
et al, 1992; Ackerman et al, 1993; Stamey et al, 1993). Recent
investigations have tried to gain an improved understanding of
tumour cell biology in order to determine the usefulness of
biomarkers such as cell cycle associated proteins like p27Kip1 or
p21WAF/Cip1 as prognostic factors in addition to classic pathological
parameters (Gleason grade, T-stage, extracapsular growth, positive
margins following radical prostatectomy) (Stamey et al, 1993).
Malignant transformation of normal somatic cells results from a
multistep process that includes the loss of an intact cell cycle
control, enhanced cellular proliferation, a lack of the induction
of apoptosis and a decreased DNA repair. A group of specific
proteins, the cyclins and cyclin-dependent kinases (cdks), are
necessary for the induction of DNA replication following the
formation of cyclin–cdk complexes that are activated by phos-
phorylation. The improved understanding of the mammalian cell
cycle has shown the loss of cell cycle control being involved in the
development and progression of malignancy (Nasmyth et al,
1996).
The cell cycle is controlled at two checkpoints, one at the G1/S
and another at the G2/M transition. The function of these check-
points is to avoid DNA replication or entry into mitosis when
substantial DNA damage has occurred (Elledge, 1996; Kawasaki
et al, 1996; Lee et al, 1997). Presently, the best understood check-
point is located at the threshold from G1 to S phase transition.
To date, seven genes, namely p15mts2/ink4B, p16cdkn2/ink4A, p18, p19,
p21WAF1/CIP1, p27Kip1 and p57, have been identified as inductors of
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cell cycle arrest at the G1 checkpoint by a negative regulatory
influence on cyclins and cdks (Kawamata et al, 1996). Recently, a
heat stable 27 kDa protein, the transcript of the p27Kip1 gene that
has been mapped on chromosome 12p12.3 (Martin et al, 1995),
has been suggested to substantially participate in cell cycle control
by preventing entry of somatic cells into the S phase of the cell
cycle (Craig et al, 1997). p27Kip1, first identified in extracts of
tumour growth factor b (TGF-b)-treated cells as an inhibitor of
cyclin E-cdk2 (Polyak et al, 1994a), binds to and inhibits the
activity of multiple cyclin–cdk complexes, including cyclin
E–cdk2, cyclin D–cdk4 and cyclin A–cdk2 (Polyak et al, 1994a,
1994b; Bullrich et al, 1995).
For patients with breast, small-cell lung and colorectal cancer
decreased expression of the p27Kip1 protein has been identified as a
predictor of a decreased long-term survival (Esposito et al, 1997;
Fredersdorf et al, 1997; Porter et al, 1997; Wu et al, 1997).
In an initial investigation, loss of physiological p27Kip1 protein
expression has been discussed as a prognostically important
biological variable only for the recurrence-free survival of patients
undergoing radical prostatectomy for the treatment of clinically
localized prostate cancer. In contrast, for 95 patients with tumours
exclusively classified as stage C during the histopathological
examination, Cote et al (1998) correlated altered expression of the
p27Kip1 protein both with the recurrence-free and overall survival
following radical prostatectomy. The purpose of the present study
was to further evaluate the involvement of p27Kip1 in the develop-
ment and progression of prostate cancer and to determine its
possible value as a predictor of the recurrence-free and overall
survival of 95 patients surgically treated for clinically localized
tumours of different stage (T2–T4) and histological grading.
PATIENTS AND METHODS
Patients
Ninety-five consecutive patients undergoing radical prostatectomy
at the Urological Department of Hannover University Medical
School between 1981 and 1994 for the treatment of clinically
localized prostate cancer for whom fresh-frozen or paraffin-
embedded tissue sections for immunohistochemical analysis were
available, were included in the present investigation. Prior to
radical prostatectomy, the presence of distant metastases was
excluded by abdominal computerized tomography (CT) scans,
X-rays of the lungs and bone scans. The median age of the patients
was 63 years (45–78 years). Following pelvic lymph node dissec-
tion and radical prostatectomy, tumour specimens were reviewed
by one pathologist and classified as T2 (49 patients, 45%), T3
(43 patients, 45%) and T4 (three patients, 4%) according to the
TNM system (Hermanek et al, 1993). Six of 49 patients with
organ-confined tumours (T2) underwent radical prostatectomy due
to the diagnosis of an incidental carcinoma (T1) during a pre-
viously performed transurethral resection for the treatment of
benign prostatic hyperplasia (BPH). The tumours were histo-
logically graded as G1 (nine tumours, 9%), G2 (58 tumours, 61%)
and G3 (28 tumours, 30%).
The final histopathological examination of the dissected
regional lymph nodes, in all patients classified as tumour-free
during intra-operatively performed histopathological examination,
revealed regional lymph node metastases in eight cases (N1, six
patients; N2, two patients). All patients were followed after
prostatectomy by transrectal ultrasound (after availability of this
diagnostic approach), bone scans and determination of the serum
prostate-specific antigen (PSA) (Hybritech, Germany) and
prostate acid phosphatase (PAP) (in patients treated before
availability of a serum PSA assay) levels every 6 months. The
median follow-up after radical prostatectomy was 56 months
(24–151 months).
In case of a suspicious digito-rectal examination (DER) or
rising PSA levels of PSA or PAP during follow-up, patients
received a CT scan of the abdomen, X-ray of the lungs and a bone
scan. In case of a rising serum PSA level on two consecutive tests
(³ 0.4 ng ml–1) without the detection of lymph node or distant
metastases needle biopsies were obtained from the vesicourethral
anastomosis to diagnose or exclude local recurrence. In cases of a
systemic tumour progression (20 patients) patients were treated
with androgen ablation (CAB) either by bilateral orchiectomy or
by the administration of a luteinizing hormone-releasing hormone
(LHRH) analogue in combination with flutamide.
Immunohistochemistry
Formalin-fixed and paraffin-embedded (21 tumours) as well as
fresh-frozen tissue sections (74 tumours) were investigated for
expression of the p27Kip1 and p21WAF/Cip proteins by an immuno-
histochemical approach. As an internal negative control for the
staining procedure, each tumour in the study was incubated with
non-immune mouse IgG instead of the primary antibody, followed
by the identical procedure for the application of the secondary
antibodies. Quiescent Balb/c 3T3 cells, induced rat embryo fibro-
blasts as well as tissue samples obtained from ten patients under-
going surgery for the treatment of BPH served as biological
positive controls respectively. In the latter tissue specimens a
relative amount of > 70% of epithelial cells exhibited a positive
immunohistochemical staining reaction for the p27Kip1 protein
(Figure 1).
During a preliminary study, fresh-frozen as well as formalin-
fixed serial cuttings obtained from ten prostate cancer specimens
Figure 1 Immunohistochemically detected expression of the p27Kip1 protein
in a tissue sample obtained from a benign prostatic hyperplasia specimen
with a relative amount of > 70% of epithelial cells exhibiting a positive
staining reaction (magnification 240-fold, ABC method)1054 M Kuczyk et al
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were immunohistochemically investigated for the p27Kip1 protein
to determine the influence of the kind of tissue fixation on the
immunohistochemical staining reaction. Although the immuno-
histochemical staining reaction observed in paraffin-embedded
tissue sections following incubation in citrate buffer for antigen
retrieval revealed a slightly higher intensity when compared with
the frozen-frozen tissue specimens, the staining pattern regarding
the amount of positively stained tumour cells was absolutely
identical, hereby indicating the applicability of the anti-p27Kip1
antibody in fresh-frozen as well as in paraffin-embedded tissue.
Following dewaxing, paraffin-embedded sections as well as
fresh-frozen slides were cut serially at 4 mm resp. 8-mm thickness
and stained for the p27Kip1 protein. Paraffin sections were picked
up on 3-aminopropyltri-ethoxysilan (APES)-coated slides, dried
for 1 day at room temperature and for an additional 3–4 h at 40°C.
For antigen retrieval, sections were incubated with 0.1 M citrate
buffer (pH 6) for 5–6 h at 70°C. Endogenous peroxidase activity
was blocked by incubation for 30 min at room temperature in 3%
hydrogen peroxidase diluted in phosphate-buffered saline (PBS)
(0.5 M, pH 7.4). After rinsing in PBS–0.1% Tween-20 the tumour-
bearing slides were incubated with normal human serum at a dilu-
tion of 1:100 in PBS for 30 min to prevent non-specific binding of
the first antibody. Then the specific monoclonal primary antibody
for the detection of the p27Kip1 protein (Clone G173–524, IgG1;
Pharmingen, San Diego, CA, USA) was added. As indicated by
the manufacturer, the anti-p27Kip1 antibody is generated by immu-
nizing mice with a full-length recombinant mouse His-fusion
protein. The anti-p27Kip1 antibody was applied at a dilution of 1:50
in PBS at room temperature for 1 h in a moist chamber respec-
tively. After rinsing with PBS–0.1% Tween-20 for 10 min a
standard streptavidin–biotin complex (Vectastain, Burlingame,
CA, USA) method was applied according to the instructions of the
manufacturer.
Classification of immunohistochemistry
Depending on the percentage of nuclei exhibiting a positive
immunohistochemical staining reaction for the p27Kip1 protein, the
tumours were classified into two groups: (1) negative reaction
or < 10% positivity regarding the relative amount of positively
stained tumour cells, (2) ³ 10% positivity. This cut-off value was
based on the previously reported experience regarding the most
suitable classification of immunohistochemistry in breast and
colorectal cancers. For the classification of the immunohisto-
chemical staining reaction, in five microscopic fields (magnifica-
tion 240-fold) per tissue slide, 400–500 tumour cells were counted
irrespective of the result of the immunohistochemical staining
reaction. For analytical purposes, the highest category obtained in
each patient was considered. The immunohistochemical staining
reaction was uniformly identified within the cell nuclei. Five
separate slides per patient were reviewed and classified by two
independent investigators. For the classification of the immuno-
histochemical staining reaction, the percentage of positively
stained tumour cells observed in each of these five tissue slides
was estimated in correlation to the total number of tumour cells
identified.
Statistical calculations
For p27Kip1 immunohistochemistry, patients were divided into
groups revealing </³ 10, </³ 40 and </³ 60% positivity and for
each of these cut-off levels, the predictive value of a decreased
p27Kip1 protein expression regarding the amount of positively
stained tumour cells was calculated for the recurrence-free as well
as the long-term survival of patients. Spearman correlation coeffi-
cients were determined to correlate p27Kip1 protein expression with
further patients’ and tumour characteristics (e.g. histological
grading, tumour stage, age and preoperative serum PSA level).
Univariate analysis using a log-rank test was employed for each
possible prognostic factor alone to determine its prognostic signifi-
cance for recurrence-free and overall survival of the patients.
Tumour-free survival was calculated from the time of radical
prostatectomy to either relapse in the form of a rising PSA level
(³ 0.4 ng ml–1 on two consecutive tests determined with an interval
of at least 50 days) or the diagnosis of local recurrence (confirmed
by the obtainment of a needle biopsy from the vesicourethral anas-
tomosis) or metastatic lesions. Overall survival was calculated
according to the Kaplan–Meier method from the time of radical
prostatectomy to either death or date of last follow-up. Finally,
multivariate Cox proportional hazards model was used to
determine whether any of the factors tested, age, tumour stage,
histological grade or percentage of immunohistochemical posi-
tivity for the p27Kip1 protein could be identified as independent
prognostic factors for the recurrence-free and the long-term
survival of the patients. The comparability of patients exhibiting
</³ 10% positivity for the p27Kip1 protein regarding other patients’
or tumour characteristics of possible prognostic value was
determined using a c2 test (Table 1).
Table 1 Prostate cancers investigated for the correlation between
decreased expression of the p27Kip protein and the recurrence-free as well as
long-term survival following radical prostatectomy
Patients’ Group 1 Group 2
characteristics (< 10% positivity) (³ 10% positivity)
n = 21 (22%) n = 74 (78%)
Age (years) 62 (48–71) 61 (45–78 years)
Tumour stage (T)
Pat. n (%)
pT1 1 (4) 5 (6)
pT2 10 (48) 33 (45)
pT3 10 (48) 33 (45)
pT4 0 3 (4)
Histological grade (G)
Pat. n (%)
G1 1 (5) 8 (11)
G2 13 (62) 45 (61)
G3 7 (33) 21 (28)
Follow-up (months) 49 (24–138) 59 (24–151)
Tumour recurrence
Pat. n (%) 7 (33) 17 (23)
Tumour-dependent
death 4 (19) 16 (22)
Pat. n (%)
Recurrence-free 14 (5–40) 31 months (7–133 months)
survival (months)
Long-term survival 33 (31–81) 59 months (4–151 (months)
Detailed characterization of patients from Group 1 (< 10% positivity) and
Group 2 (³ 10% positivity). Patients from Group 1 and 2 were comparable
regarding other characteristics of possible prognostic value (c2).Expression of p27Kip1 in prostate cancer1055
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RESULTS
Association of p27Kip1 protein expression with
recurrence-free survival
Univariate analysis using the log-rank test was employed for
each biological variable alone to determine its significance for
recurrence-free survival. Out of 95 prostate cancer specimens
investigated for p27Kip1 protein expression, 21 (22%) patients
exhibited a completely negative (Figure 2) or a positive staining
reaction in < 10% of tumour cells (Group 1) and 74 (78%) patients
(Group 2) a retained immunohistochemical staining reaction in at
least 10% of tumour cells (Figure 3). Nuclear reactivity for the
p27Kip1 protein was seen in the luminal cells as well as in the basal
cell layers of all BPH samples investigated.
Seven of 21 (33%) patients with a negative staining reaction or
a retained p27Kip1 protein expression in < 10% of tumour cells
(Group 1) developed tumour progression compared with 17 of 74
(23%) patients from Group 2 (³10 positivity) (median follow-up
was 49 months (24–138 months) for patients from Group 1 and
59 months (24–151 months) for Group 2 patients). The median
recurrence-free survival following radical prostatectomy was 14
months (5–40 months) for Group 1 patients and 31 months (7–133
months) for patients from Group 2 (P= 0.02; log-rank test)
(Table 2, Figure 4). There were no imbalances for other investi-
gated variables between the two groups (Table 1). A negative
staining reaction as a predictor of recurrence-free survival did not
achieve statistical significance at the other cut-off values (</³40
and </³60% positivity) calculated (data not shown).
Statistical analysis of further prognostic parameters
Univariate analysis demonstrated that tumour-free survival
following radical prostatectomy was independent of age
(P= 0.12), histological grading (P= 0.07), the presence of
regional lymph node metastases (P= 0.45), as well as the serum
PSA level (P= 0.23). Tumour stage (P= 0.03) and, with a cut-off
value of 10%, retained expression of the p27Kip1 protein was
significantly correlated with the recurrence-free survival of the
patients (P= 0.02). In multivariate analysis, reactivity for the
p27Kip1 protein (P= 0.04) proved to be the only statistically rele-
vant prognostic factor for the recurrence-free survival of the
patients.
Spearman correlation coefficients were calculated to determine
if p27Kip1 positivity could be correlated with further tumour
or patient’s characteristics. Immunohistochemically detected
expression of the p27Kip1 protein was demonstrated as a variable
independent from tumour stage (P= 0.31), histological grading
Figure 2Complete loss of p27Kip1 protein expression in a radical prostate
cancer specimen (T3,G2) (ABC method, magnification 240-fold)
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Figure 3Immunohistochemically detected staining pattern for the p27 Kip1
protein in a radical prostate cancer specimen (T3,G2): retained expression
of the p27Kip1 protein in > 10% of tumour cells (ABC method, magnification
240-fold)
Figure 4Recurrence-free survival following radical prostatectomy,
calculated according to the Kaplan–Meier method. Classification into Group 1
(< 10% positively stained tumour cells) and Group 2 (³10% positivity): Group
2 patients had a significantly decreased recurrence-free survival following
radical prostatectomy (P = 0.02)1056 M Kuczyk et al
British Journal of Cancer (1999) 81(6), 1052–1058 © 1999 Cancer Research Campaign
(P = 0.37), patients age (P = 0.34), the serum PSA level (P = 0.64)
and the lymph node status (P = 0.62).
Association of p27Kip1 protein expression with overall
survival
After a median follow-up of 56 months (24–151 months), 20 of 95
(21%) patients had died from tumour progression. During the
follow-up period, four of 21 (19%) patients from Group 1 (nega-
tive reaction or < 10% positivity) died from tumour progression, in
contrast to 16 of 74 (22%) patients from Group 2 (³ 10% positivity
for the p27Kip1 protein). The calculated median survival times were
33 months (31–81 months) for patients from Group 1 and 59
months (4–151 months) for Group 2 patients. For one of the
patients classified into Group 2 who died from tumour progression
4 months after surgery, the final histopathological examination of
the intraoperatively dissected lymph nodes revealed regional
lymph node metastases (N2). Although there was a tendency
towards a decreased long-term survival for patients revealing loss
of p27Kip1 protein expression within the primary tumours, the
difference between Group 1 and Group 2 patients was not statisti-
cally significant (P = 0.12) (Table 2). Accordingly, the level of
statistical significance for overall survival was not reached with all
other cut-off values (</³ 40 and </³ 60%) for the amount of posi-
tively stained tumour cells (data not shown).
Statistical analysis of further prognostic parameters
Univariate statistical analysis demonstrated that the time of
survival following radical prostatectomy was independent of
age (P = 0.23), the diagnosis of regional lymph node metastases
(P = 0.34), the histological grading (P = 0.08), the preoperatively
determined serum PSA level (P = 0.31) and positivity for the
p27Kip1 protein (P = 0.12). Tumour stage was the only biological
variable significantly correlated with the long-term survival of the
patients (P = 0.04). In a multivariate analysis, none of the afore-
mentioned parameters was identified as an independent prognostic
factor for overall survival.
DISCUSSION
For the majority of human malignancies, previously reported
investigations in several human tumours including prostate cancer
failed to demonstrate any alteration at the p27Kip1 gene locus
(Bullrich et al, 1995; Ferrando et al, 1996; Spirin et al, 1996).
Therefore, reduced p27Kip1 protein expression as meanwhile identi-
fied in a variety of human malignancies including colorectal carci-
nomas, breast cancer and non-small-cell lung cancer specimens
(Fredersdorf et al, 1997; McGarvey and Malkowicz, 1997; Yasui
et al, 1997), has been initially suggested to result from a post-
translational regulatory influence of growth factors like TGFb or
cAMP (Kato et al, 1994; Ferrando et al, 1996; Spirin et al, 1996;
Esposito et al, 1997; Yasui et al, 1997). Recently, it has been
suggested that the lower or even undetectable protein level in
tumorous tissue specimens when compared with normal somatic
cells more likely results from an increased degradation of the
p27Kip1 protein than from an altered p27Kip1 gene transcription or
p27Kip1 mRNA stability (Ponce-Castaneda, 1995).
Therefore, the investigation of cancerous tissue specimens for
p27Kip1 alterations on the protein level by immunohistochemistry,
for example, appears as the most suitable analytical approach to
clarify the possible involvement of p27Kip1 in the development and
progression of human malignancies and to further evaluate the role
as a biological variable of possible prognostic importance (Cote
et al, 1998).
Whereas for non-small-cell lung cancer, colorectal and breast
cancers (Esposito et al, 1997; Porter et al, 1997), decreased p27Kip1
protein expression was correlated with a shorter overall survival of
the patients, Fredersdorf et al (1997) also reported contradictory
findings for a subset of highly proliferative breast cancer cell lines
exhibiting high level p27Kip1 expression. An initial study in bladder
cancer, investigating the expression of p27Kip1 mRNA in 14 super-
ficial and 14 muscle invasive tumour specimens, reported a
decreased level of the p27Kip1 transcript in invasive compared with
superficial lesions (McGarvey et al, 1997).
To date, the prognostic value of a decreased p27Kip1 protein
expression for patients undergoing radical prostatectomy for the
treatment of clinically localized prostate cancer has not yet been
well determined. Initially, Yang et al (1998) identified absent or
low p27Kip1 protein expression as an adverse prognostic parameter
for patients with clinically organ-confined prostate cancer (Yang
et al, 1998). However, loss of p27Kip1 protein expression was not
identified as a predictor of long-term survival following radical
prostatectomy (Yang et al, 1998). Recently, Cote et al (1998)
investigated the prognostic value of decreased p27Kip1 protein
expression for the recurrence-free and overall survival of 96 stage
C prostate cancer patients (median follow-up: 9.6 years) under-
going radical prostatectomy. For a cut-off value of 10%, loss of
p27Kip1 protein expression was inversely correlated with the
Gleason score and clearly identified as an independent prognostic
parameter both for the recurrence-free and long-term survival of
the patients.
In the present investigation the median recurrence-free survival
following radical prostatectomy was 14 months (5–40 months) and
31 months (7–133 months) for patients without and with retained
Table 2 Patients’ and tumour characteristics evaluated as parameters of
possible prognostic importance for the recurrence-free and overall survival of
95 patients undergoing radical prostatectomy for the treatment of clinically
localized prostate cancer
Factor investigated Univariate analysis Multivariate analysis
(log-rank test) (Cox regression)
Recurrence-free survival
following radical
prostatectomy
Tumour stage Yes (P = 0.03) No (P = 0.09)
Histological grading No (P = 0.07) No (P = 0.32)
Lymph node status No (P = 0.45) No (P = 0.83)
Patients’ age No (P = 0.12) No (P = 0.14)
IHC for p27Kip1 Yes (P = 0.02) Yes (P = 0.04)
(cut-off value 10%)
Overall survival following
radical prostatectomy
Tumour stage Yes (P = 0.04) No (P = 0.31)
Histological grading Nos (P = 0.08) No (P = 0.23)
Lymph node status No (P = 0.18) No (P = 0.57)
Patient’s age No (P = 0.23) No (P = 0.48)
IHC for p27Kip1 No (P = 0.12) No (P = 0.19)
(cut-off value 1%)
IHC: immunohistochemistry.expression (³ 10% positivity) of the p27Kip1 protein. This differ-
ence proved to be statistically significant (P = 0.02). Whereas in
univariate statistical analysis tumour stage in combination with
altered p27Kip1 protein expression was identified as predictor of an
early tumour recurrence following radical prostatectomy, during
multivariate analysis loss of p27Kip1 protein expression was identi-
fied as the only independent prognostic predictor of recurrence-
free survival.
However, in contrast to the results reported by Cote et al (1998)
and in accordance with the observation by Yang et al (1998), in our
study decreased expression of the p27Kip1 protein was not corre-
lated to the long-term survival of the patients. This observation
might be explained with the high frequency of low-stage tumours
(≤ T2) (52%) included in our study, whereas the investigation by
Cote et al (1998) exclusively evaluated the prognostic importance
of p27Kip1 in locally advanced (Stage C) prostate cancer specimens.
Additionally, Cote et al (1998) do not give any information on the
kind of adjuvant therapy applied in case of local recurrence or
systemic tumour progression. Due to the role of the p27Kip1 protein
during cell cycle regulation its ability to predict tumour respon-
siveness regarding hormone ablation or adjuvant radiotherapy
appears at least questionable. Therefore, according to our study
and with regard to the results reported by Yang et al (1998), the
observation of decreased p27Kip1 protein expression might rather
help identifying patients at high risk for tumour recurrence or
systemic progression who urgently need early adjuvant therapy.
For clinically localized prostate cancer recent studies strongly
indicate that the determination of p53 inactivation allows the
identification of a highly aggressive subgroup of prostatic tumours
with decreased recurrence-free and long-term survival following
radical prostatectomy (Kuczyk et al, 1998). The outcome of the
present study seems to indicate that in addition to p53 and already
established prognostic parameters like Gleason score or tumour
stage, the detection of altered p27Kip1 expression might help to
establish a therapeutic regimen adjusted to the aggressiveness of
the individual tumour, although this result will have to be
confirmed during further prospective investigations including a
range of prognostically important biological variables like p27Kip1
or p53. Therefore, further insight in the role of cell cycle associ-
ated proteins for the development and progression of prostate
cancer might contribute to the establishment of effective
approaches aiming at the reconstitution of functionally altered cell
cycle regulatory mechanisms.
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